Taken together, our data suggest that targeting HIF2α cooperates with ATRA for differentiation induction and removes a negative feedback loop of HIF2α upregulation that may be implicated in promoting AML self‐renewal, thus potentiating ATRA‐based therapies in AML. Here, EPAS1 is linked to acute myeloid leukemia.